Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


In the article, with regard to current clinical recommendations, the place of combined antihypertensive therapy, especially triple drugs regimens, is considered in the treatment of patients with arterial hypertension. Special focus is given to the body of evidence for the efficacy of valsartan and amlodipine, as the reference drug of angiotensin II receptor blockers and calcium channel blockers, respectively. Not only their high antihypertensive properties are demonstrated, but also a favorable effect on target-organ protection and prognosis is described. In particular, the possibilities of valsartan in reducing the severity of left ventricular hypertrophy and microalbuminuria are described, and its unique properties in the class of sartans that allow the use of this drug in patients with ischemic heart disease and chronic heart failure are emphasized. Data on the antiatherosclerotic effects of amlodipine and its proven ability to reduce cardiovascular risk are presented. Current data are presented about their use in a fixed-dose combination with hydrochlorothiazide, including real clinical practice settings. The evidence base of high clinical efficacy, safety and metabolic neutrality of the triple combination of antihypertensive drugs valsartan, amlodipine and hydrochorothiazide is presented. The issues of increasing adherence of patients to treatment when prescribing fixed-dose combinations are considered. An algorithm for the selection of antihypertensive drugs in the form of monotherapy and combination therapy of two or three drugs depending on the clinical situation (the presence of certain target-organs damages and associated clinical conditions, primarily ischemic heart disease, atherosclerosis of carotid arteries and chronic heart failure) and the severity of the additional risk of cardiovascular complications.

About the Authors

O. D. Ostroumova
A.I. Evdokimov Moscow State University of Medicine and Dentistry; 2 I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

MD, PhD, Professor, Chair of Faculty Therapy and Occupational Diseases, Delegatskaya ul. 20/1, Moscow, 127473;

Professor, Chair of Clinical Pharmacology and Propaedeutics of Internal Diseases, Trubetskaya ul. 8, Moscow, 11999

A. I. Kochetkov
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Russian Federation

MD, PhD, Assistant, Chair of Faculty Therapy and Occupational Diseases,

Delegatskaya ul. 20/1, Moscow, 127473 

A. V. Starodubova
Federal Research Centre of Nutrition, Biotechnology and Food Safety; Pirogov Russian National Research Medical University
Russian Federation

MD, PhD, Deputy Director for Scientific and Medical Work, Ust’inskiy pr. 2/14, Moscow, 109240;

Professor, Chair of Faculty Therapy, Ostrovitianova ul. 1, Moscow 117997

I. V. Goloborodova
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Russian Federation
MD, PhD, Associate Professor, Chair of Faculty Therapy and Occupational Diseases, Delegatskaya ul. 20/1, Moscow, 127473

E. A. Smolyarchuk
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

MD, PhD, Associate Professor, Chair of Clinical Pharmacology and Propaedeutics of Internal Diseases,

Trubetskaya ul. 8, Moscow, 11999


1. WHO. A global brief on hypertension. 2013. [cited 2018 Jun 12]. Available from:

2. Chazova I.E., Oschepkova E.V., Zhernakova Yu.V., et al. Diagnosis and treatment of arterial hypertension. Clinical guidelines (2013). [cited 2018 Jun 12]. Available from: (In Russ.) [Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В., и др. Диагностика и лечение артериальной гипертонии. Клинические рекомендации (2013). [цитировано 12.06.2018]. Доступно на:].

3. Mancia G., Fagard R., Narkiewicz K., et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281- 357. doi:10.1093/eurheartj/eht151

4. Erdine S. How well is hypertension controlled in Europe? J Hypertens. 2000 Sep;18(9):1348-9.

5. Boytsov S.A., Balanova Y.A., Shalnova S.A., et al. Arterial hypertension among individuals of 25-64 years old: prevalence, awareness, treatment and control. By the data from ESSE study. Cardiovascular Therapy and Prevention. 2014;13(4):4-14. (In Russ.) [Бойцов С.А., Баланова Ю.А., Шальнова С.А., и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная Терапия и Профилактика. 2014;13(4):4-14]. doi: 10.15829/1728-8800-2014-4-4-14.

6. ESC–ESH: 2018 guidelines for the management of arterial hypertension [internet]. Barcelona: European Society of Cardiology–European Society of Hypertension; 28th European Meeting on Hypertension and Cardiovascular Protection; June 8-11, 2018. [cited 11. 06. 2018]. Available from:

7. Gradman A.H., Basile J.N., Carter B.L., Bakris G.L. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(1):42-50. doi: 10.1016/j.jash.2010.02.005.

8. Bakris G.L. The importance of blood pressure control in the patient with diabetes.Am J Med. 2004 Mar 8;116 Suppl 5A:30S-38S. doi: 10.1016/j.amjmed.2003.10.018.

9. Dahlöf B., Sever P.S., Poulter N.R., et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005;366:895-906. doi: 10.1016/S0140-6736(05)67185-1.

10. Jamerson K., Weber M.A., Bakris G.L., et al.; ACCOMPLISH Trial Investigators.Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-28.

11. Maksimov M.L., Ermolaeva A.S., Dralova O.V. When should I appoint valsartan? The use of the angiotensin receptor blocker valsartan in the pharmacotherapy of cardiovascular diseases. Arterial'naya Gipertenziya. 2013;19(5):458-71. (In Russ.) [Максимов М.Л., Ермолаева А.С., Дралова О.В. Когда назначать валсартан? Применение блокатора рецепторов ангиотензина валсартана в фармакотерапии сердечно-сосудистых заболеваний. Артериальная Гипертензия. 2013;19(5):458-71].

12. Julius S., Weber M.A., Kjeldsen S.E., et al. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension. 2006;48(3):385-391. doi: 10.1161/01.HYP.0000236119.96301.f2

13. Ridker P.M., Danielson E., Rifai N., Glynn R.J.; Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension. 2006;48(1):73-79. doi: 10.1161/01.HYP.0000226046.58883.32

14. Ostroumova O.D., Guseva T.F., Shorikova E.G. The use of the drug Valsakor in arterial hypertension: the results of the Slovenian multicentre study. Russkiy Meditsinskiy Zhurnal. 2010;18(2):642. (In Russ.) [Остроумова О.Д., Гусева Т.Ф., Шорикова Е.Г. Применение препарата Вальсакор при артериальной гипертонии:результаты словенского многоцентрового исследования. Русский Медицинский Журнал. 2010;18(2):642].

15. Chazova I.E.,Martynyuk T.V.,Accetto R., et al. Results ofthe international clinical studyVICTORY: efficacy and safety of antihypertensive monotherapy with valsartan (Valsacor®) and its fixed combination with hydrochlorothiazide (Valsacor® H) in patients with arterial hypertension 1-2 degrees. Sistemnyye Gipertenzii. 2017;2:80-9. (In Russ.) [Чазова И.Е., Мартынюк Т.В., Accetto R, и др. Итоги международного клинического исследованияVICTORY: эффективность и безопасность антигипертензивной монотерапии валсартаном (Вальсакор®) и его ФК с гидрохлоротиазидом (Вальсакор® Н) у пациентов с артериальной гипертонией 1-2-степени. Системные Гипертензии. 2017;2:80-9].

16. Karpov Yu.A., Gendlin G.E. The effectiveness of angiotensin receptor blockers at different stages of the cardiovascular continuum focuses on valsartan. Atmosfera. Novosti Kardiologii. 2012;2:27-31. (In Russ.) [Карпов Ю.А., Гендлин Г.Е. Эффективность блокаторов рецепторов ангиотензина на разных этапах сердечно-сосудистого континуума фокус на валсартан. Атмосфера. Новости Кардиологии. 2012;2:27-31].

17. Karpov, Yu.A. Valsartan: central to the treatment of a cardiac patient. Atmosfera. Novosti Kardiologii. 2014;2:52-6. (In Russ.) [Карпов, Ю.А. Валсартан: центральное место в лечении кардиологического больного. Атмосфера. Новости Кардиологии. 2014;2:52-6].

18. Kannel W.B. Left ventricular hypertrophy as a risk factor in arterial hypertension. Eur Heart J. 1992;13(Suppl D):82-8.

19. Dinneen S.F., GersteinH.C. The association of microalbuminuria and mortality in non-insulin-dependent diabetes ' mellitus. A systematic overview of the literature. Arch Intern Med.1997;157:1413-8.

20. Samuelsson O. Hypertension in middle- aged men:management,morbidity and prognostic factors during long-term hypertensive care. Acta Med Scand.1985;702(suppl.):1-79.

21. Sorokin E.V. Cardiovascular diseases, microalbuminuria and statins: is a new breakthrough expected? Russkiy Meditsinskiy Zhurnal. 2010;22:1327. (In Russ.) [Сорокин Е.В. Сердечно-сосудистые заболевания, микроальбуминурия и статины: ожидается ли новый прорыв? Русский Медицинский Журнал. 2010;22:1327].

22. Grona N.V. Microalbuminuria as an early diagnostic, clinical and prognostic marker for arterial hypertension. Vestnik Problem Biologii i Meditsiny. 2014;2(3):11-7 (In Russ.) [Грона Н.В. Микроальбуминурия как ранний диагностический, клинический и прогностический маркер при артериальной гипертензии. Вестник Проблем Биологии и Медицины. 2014;2(3):11-7].

23. Preobrazhenskiy D.V., Marenich A.V., Romanova N.E. et al. Microalbuminuria: diagnostic, clinical and prognostic significance (Part I). Russian Cardiology Journal. 2000;3:56-9. (In Russ.) [Преображенский Д.В., Маренич А.В., Романова Н.Е. и др. Микроальбуминурия: диагностическое, клиническое и прогностическое значение (часть I). Российский Кардиологический Журнал. 2000;3:56-9].

24. Viberti G., Wheeldon N.M.; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation. 2002;106(6):672-8. Doi: 10.1161/01.CIR.0000024 416.33113.0A.

25. Bedigian M.P. Improving the prognosis of diabetic patients: evaluating the role of intensive versus moderate blood pressure control with selective angiotensin II receptor blocker (ARB) therapy. J Renin Angiotensin Aldosterone Syst. 2000;1(2 Suppl):S25-28. doi: 10.3317/jraas.2000.050.

26. Uzu T., Sawaguchi M., Maegawa H., Kashiwagi A. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Diabetes Care. 2007;30(6):1581-3. doi: 10.2337/dc06-2493.

27. Hollenberg N.K., ParvingH.H.,Viberti G., et al.Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007;25(9):1921-6. doi: 10.1097/HJH.0b013e328277596e.

28. McMurray J., Solomon S., Pieper K., et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol. 2006;47(4):726-33. doi: 10.1016/j.jacc.2005.09.055.

29. Ibanez B., James S., Agewall S., et al.; ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77. doi: 10.1093/eurheartj/ehx393.

30. Peters S., Götting B., Trümmel M., et al. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the AL-PREST trial. J Invasive Cardiol. 2001;13(2):93-97.

31. Peters S., Trümmel M., Meyners W., et al. Valsartan versus ACE inhibition after bare metal stent implantation - results of the VALVACE trial. Int J Cardiol. 2005;98(2):331-335.

32. Maggioni A.P., Latini R., Carson P.E., et al.; Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (ValHeFT). Am Heart J. 2005;149(3):548-57. doi: 10.1016/j.ahj.2004.09.033

33. Cohn J.N., Tognoni G.; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345(23):1667- 75. doi: 10.1056/NEJMoa010713.

34. Nissen S.E., Tuzcu E.M., Libby P, et al. for the CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217-26. doi: 10.1001/jama.292.18.2217.

35. Brener S.J., Ivanc T.B., Poliszczuk R., et al. Antihypertensive therapy and regression of coronary artery disease: insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials. Am Heart J. 2006;152(6):1059-63. doi: 10.1016/j.ahj.2006.07.022

36. Pitt B., Byington R.P., Furberg C.D., et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000;102(13):1503-10. doi: 10.1161/01.CIR.102.13.1503.

37. Jamerson K., Weber M.A., Bakris G.L., et al., for the Accomplish trial investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428. doi: 10.1056/NEJMoa0806182.

38. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2988-97. doi: 10.1001/jama.288.23.2981.

39. Kizilirmak P., Berktas M., Uresin Y., Yildiz O.B. The efficacy and safety of triple vs dual combination of angiotensin II receptor blocker and calcium channel blocker and diuretic: a systematic review and meta-analysis.J Clin Hypertens (Greenwich). 2013;15(3):193-200. Doi: 10.1111/jch.12040.

40. Destro M., Crikelair N., Yen J., Glazer R. Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients. Vasc Health Risk Manag. 2010;6:821-7. doi: 10.2147/VHRM.S11522.

41. Calhoun D.A., Lacourcière Y., Chiang Y.T., Glazer R.D. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009;54(1):32-9. doi: 10.1161/HYPERTENSIONAHA.109.131300.

42. Lacourcière Y., Crikelair N., Glazer R.D., et al. 24-Hour ambulatory blood pressure control with tripletherapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension. J Hum Hypertens. 2011;25(10):615-22. doi: 10.1038/jhh.2010.115.

43. Gosse P., Schumacher H. Early morning blood pressure surge. J Clin Hypertens (Greenwich). 2006;8:584-9. doi: 10.1111/j.1524-6175.2006.04773.x.

44. Assaad-Khalil S.H., Najem R., Sison J., et al. Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups. Vascular Health and Risk Management. 2015;11:71-8. doi:10.2147/VHRM.S76599.

45. Hagendorff A., Kurz I., Müller A., Klebs S. Evaluation of effectiveness and safety of amlodipine/valsartan/hydrochlorothiazide single-pill combination therapy in hypertensive patients: an observational study. J Drug Assess. 2014;3(1):1-9. doi: 10.3109/21556660.2014.884506.


For citations:

Ostroumova O.D., Kochetkov A.I., Starodubova A.V., Goloborodova I.V., Smolyarchuk E.A. TRIPLE ANTIHYPERTENSIVE THERAPY: FOCUS ON EFFICACY AND PROGNOSIS. Rational Pharmacotherapy in Cardiology. 2018;14(3):458-468. (In Russ.)

Views: 894

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)